In vitro anti-estrogenic potential of FertiZen-R™- a nutraceutical ingredient for estrogen modulation

Background: According to CDC, polycystic ovarian syndrome (PCOS) is responsible for infertility in women with 6-12% incidences all over the world. The current treatment options available have several side effects such as amenorrhea and obesity amongst others. Dietary interventions non-estrogenic androgen-suppressing foods along nutraceutical products considered treating PCOS minimum effects. One product of Zenherbs lab called FertiZen-R™ a combination three phytochemicals from plants viz., Foeniculum vulgare, Linum Usitatissimum, Glycyrrhiza glabra, hibiscus extract developed treat control PCOS. Methods: was quantified presence glycyrrhizic acid, polyphenols, saponins. It further tested estrogenic/anti-estrogenic potential on estrogen-positive breast cancer cell line (MCF-7) using an E-Screen assay. Results: showed 5% glycyrrhizinic saponins, 2-3% polyphenols. exhibited strong anti-estrogenic 40-50% inhibition concentrations low 0.156 mg/ml like tamoxifen (IC50 at mg/ml), while inositol, natural growth promoter, no effect viability. Conclusions: when in-vitro can be used even ER-positive cells. However, clinical studies determine dosage are required warrant FertiZen-R™.